M3T01
/ Providence Health & Services, BlueSphere Bio
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Interim results of a phase I clinical trial evaluating Fas ligand (FasL) blocking antibody M3T01 in adults with advanced treatment-refractory solid tumors
(AACR 2026)
- "Abstract is embargoed at this time."
Clinical • Metastases • P1 data • Oncology • Solid Tumor • FASLG
1 to 1
Of
1
Go to page
1